BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) today announced the completion of its Scientific Advisory Board (SAB), which is composed of eight industry leading experts from the cardiovascular and neurological medical communities. The SAB will meet periodically with our scientific and development personnel as well as members of the Company’s executive management to discuss and advise the Company on its ongoing and future clinical, regulatory and development programs, including its pivotal patent foramen ovale (PFO)/stroke and transient ischemic attack trial, CLOSURE I.
